Arrowhead Research Corp. (NASDAQ:ARWR) shares saw unusually-high trading volume on Thursday . Approximately 2,357,179 shares changed hands during mid-day trading, an increase of 270% from the previous session’s volume of 636,817 shares.The stock last traded at $7.15 and had previously closed at $6.34.

ARWR has been the subject of several recent research reports. Jefferies Group restated a “hold” rating and issued a $4.75 price target on shares of Arrowhead Research Corp. in a research report on Wednesday, May 11th. Cantor Fitzgerald initiated coverage on shares of Arrowhead Research Corp. in a research report on Wednesday. They issued a “buy” rating and a $15.00 price target for the company. Piper Jaffray Cos. decreased their price target on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. Vetr upgraded shares of Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 price target for the company in a research report on Wednesday, April 20th. Finally, Chardan Capital initiated coverage on shares of Arrowhead Research Corp. in a research report on Thursday, May 19th. They issued a “buy” rating and a $12.00 price target for the company. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $10.44.

The stock’s market capitalization is $428.90 million. The firm has a 50 day moving average of $5.83 and a 200-day moving average of $5.25.

Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.05. The company had revenue of $39.58 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period in the previous year, the firm posted ($0.27) earnings per share. The firm’s revenue for the quarter was down 68.0% compared to the same quarter last year. On average, equities analysts anticipate that Arrowhead Research Corp. will post ($1.30) EPS for the current year.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.